Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors

First Posted Date
2022-11-17
Last Posted Date
2024-07-09
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
68
Registration Number
NCT05620862
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation

First Posted Date
2022-11-09
Last Posted Date
2024-10-26
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
312
Registration Number
NCT05610163
Locations
🇺🇸

Lutheran Hospital - Cancer Centers of Colorado, Golden, Colorado, United States

🇺🇸

Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States

🇺🇸

Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States

and more 632 locations

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

First Posted Date
2022-10-27
Last Posted Date
2022-11-29
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
40
Registration Number
NCT05595889

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

First Posted Date
2022-09-21
Last Posted Date
2024-12-17
Lead Sponsor
University Hospital, Grenoble
Target Recruit Count
52
Registration Number
NCT05546853
Locations
🇫🇷

CHU de GRENOBLE ALPES, Grenoble, Alpes, France

🇫🇷

CHU de BORDEAUX, Bordeaux, France

🇫🇷

CHRU Lille, Lille, France

and more 6 locations

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

First Posted Date
2022-09-19
Last Posted Date
2024-12-17
Lead Sponsor
Kimberly Perez, MD
Target Recruit Count
8
Registration Number
NCT05546411
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

First Posted Date
2022-07-18
Last Posted Date
2024-07-09
Lead Sponsor
AUM Biosciences Pte Ltd
Target Recruit Count
120
Registration Number
NCT05462236
Locations
🇦🇺

Ballarat Oncology and Haematology, Wendouree, Victoria, Australia

🇦🇺

Pindara Private Hospital, Gold Coast Cancer Care, Benowa, Queensland, Australia

🇦🇺

Cabrini Hospital, Malvern, Victoria, Australia

and more 2 locations

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

First Posted Date
2022-07-18
Last Posted Date
2024-03-04
Lead Sponsor
BeiGene
Target Recruit Count
96
Registration Number
NCT05461794
Locations
🇨🇳

Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu, Sichuan, China

🇨🇳

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

🇨🇳

The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China

and more 24 locations

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

First Posted Date
2022-07-01
Last Posted Date
2024-12-11
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
45
Registration Number
NCT05440786
Locations
🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

🇺🇸

The Regents of the University of California - Los Angeles (UCLA Pediatrics), Los Angeles, California, United States

🇺🇸

Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States

and more 24 locations

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

First Posted Date
2022-06-28
Last Posted Date
2024-01-17
Lead Sponsor
Fudan University
Target Recruit Count
39
Registration Number
NCT05435313
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

FOLFIRINOX + NIS793 in Pancreatic Cancer

First Posted Date
2022-06-14
Last Posted Date
2024-06-25
Lead Sponsor
Colin D. Weekes, M.D., PhD
Target Recruit Count
4
Registration Number
NCT05417386
Locations
🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy